Free Trial
NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Price, News & Analysis

Xilio Therapeutics logo
$1.00 +0.00 (+0.24%)
(As of 11:36 AM ET)

About Xilio Therapeutics Stock (NASDAQ:XLO)

Key Stats

Today's Range
$0.98
$1.04
50-Day Range
$0.73
$1.44
52-Week Range
$0.49
$1.93
Volume
21,736 shs
Average Volume
531,278 shs
Market Capitalization
$43.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
50th Percentile Overall Score

XLO MarketRank™: 

Xilio Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 624th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xilio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Xilio Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Xilio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.12) to ($0.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xilio Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xilio Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xilio Therapeutics has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Xilio Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.86% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently increased by 277.96%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Xilio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Xilio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.86% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently increased by 277.96%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Xilio Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Xilio Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    3 people have searched for XLO on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of Xilio Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xilio Therapeutics' insider trading history.
Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

XLO Stock News Headlines

Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00
DeFi Coin on Verge of Breakout!
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
Xilio Therapeutics Reports Q3 2024 Progress and Financials
Xilio Therapeutics Advances Cancer Drug and Financial Outlook
TD Cowen Keeps Their Buy Rating on Xilio Therapeutics (XLO)
See More Headlines

XLO Stock Analysis - Frequently Asked Questions

Xilio Therapeutics' stock was trading at $0.55 at the start of the year. Since then, XLO stock has increased by 80.0% and is now trading at $0.99.
View the best growth stocks for 2024 here
.

Xilio Therapeutics, Inc. (NASDAQ:XLO) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.01. The business had revenue of $2.36 million for the quarter, compared to analyst estimates of $30 million.

Xilio Therapeutics (XLO) raised $125 million in an initial public offering on Friday, October 22nd 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share.

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include PayPal (PYPL), Achilles Therapeutics (ACHL), JPMorgan Chase & Co. (JPM), AT&T (T), United Microelectronics (UMC), Adverum Biotechnologies (ADVM) and Atai Life Sciences (ATAI).

Company Calendar

Last Earnings
8/08/2024
Today
11/13/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
4/07/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XLO
Fax
N/A
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+301.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-76,400,000.00
Pretax Margin
-1,359.37%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.48 per share

Miscellaneous

Free Float
41,672,000
Market Cap
$43.85 million
Optionable
Not Optionable
Beta
-0.24
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:XLO) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners